|
Features of Selective Kinase Inhibitors
|
journal
|
June 2005 |
|
NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions
|
journal
|
June 2015 |
|
Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis
|
journal
|
April 2016 |
|
Structure and Regulation of the CDK5-p25nck5a Complex
|
journal
|
September 2001 |
|
Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition
|
journal
|
January 2018 |
|
Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma
|
journal
|
September 2021 |
|
The human phosphatase CDC 14A modulates primary cilium length by regulating centrosomal actin nucleation
|
journal
|
November 2018 |
|
Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling
|
journal
|
January 2013 |
|
Targeting the cyclin-dependent kinase 5 in metastatic melanoma
|
journal
|
March 2020 |
|
Cdk1 is sufficient to drive the mammalian cell cycle
|
journal
|
August 2007 |
|
Molecular roles of Cdk5 in pain signaling
|
journal
|
September 2009 |
|
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
|
journal
|
July 2017 |
|
TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice
|
journal
|
January 2017 |
|
CDK5 inhibition in�vitro and in vivo induces cell death in�myeloma and overcomes the obstacle of bortezomib resistance
|
journal
|
March 2020 |
|
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD
|
journal
|
November 2012 |
|
Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery
|
journal
|
July 2016 |
|
Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8
|
journal
|
July 2018 |
|
Nde1-mediated inhibition of ciliogenesis affects cell cycle re-entry
|
journal
|
March 2011 |
|
The history and future of targeting cyclin-dependent kinases in cancer therapy
|
journal
|
January 2015 |
|
A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation
|
journal
|
October 2010 |
|
Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5
|
journal
|
January 1997 |
|
Rational Approaches to Improving Selectivity in Drug Design
|
journal
|
January 2012 |
|
Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells
|
journal
|
December 2015 |
|
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
|
journal
|
July 2010 |
|
Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2
|
journal
|
September 2012 |
|
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
|
book
|
March 2000 |
|
Structural and Mechanistic Insights into the PAPS-Independent Sulfotransfer Catalyzed by Bacterial Aryl Sulfotransferase and the Role of the DsbL/DsbI System in Its Folding
|
journal
|
March 2014 |
|
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
|
journal
|
September 2005 |
|
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
|
journal
|
September 2018 |
|
CDK5 in oncology: recent advances and future prospects
|
journal
|
October 2017 |
|
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
|
journal
|
August 2017 |
|
Autosomal dominant polycystic kidney disease
|
journal
|
April 2007 |
|
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
|
journal
|
December 2012 |
|
Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity
|
journal
|
August 2016 |
|
Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9
|
journal
|
April 2016 |
|
An Unusual Member of the Cdk Family: Cdk5
|
journal
|
January 2008 |
|
Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease
|
journal
|
October 2020 |
|
Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease
|
journal
|
April 2020 |
|
Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain
|
journal
|
January 2019 |
|
Cyclin dependent kinase 5: A novel avenue for Alzheimer’s disease
|
journal
|
June 2017 |
|
Conservation, Variability and the Modeling of Active Protein Kinases
|
journal
|
October 2007 |
|
CDK5: A Unique CDK and Its Multiple Roles in the Nervous System
|
journal
|
April 2019 |
|
TFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke
|
journal
|
January 2017 |
|
Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors
|
journal
|
September 2012 |
|
Ischemic Stroke Injury Is Mediated by Aberrant Cdk5
|
journal
|
June 2014 |
|
Discovery of CDK5 Inhibitors through Structure-Guided Approach
|
journal
|
March 2019 |
|
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1 H -1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V 2 receptor antagonist
|
journal
|
August 1999 |
|
Cyclin-dependent kinases
|
journal
|
January 2014 |
|
Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
|
journal
|
May 2013 |
|
Induction of CRMP‐2 phosphorylation by CDK5 restricts the repair of damaged optic nerve
|
journal
|
December 2018 |
|
A kinase of many talents: non-neuronal functions of CDK5 in development and disease
|
journal
|
January 2020 |
|
Gini Coefficient: A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases †
|
journal
|
November 2007 |
|
Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: Synthesis, neuronal cell culture investigations, and CDK5 docking studies
|
journal
|
July 2011 |
|
Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease
|
journal
|
July 2013 |
|
Molecular Basis of Differential Selectivity of Cyclobutyl-Substituted Imidazole Inhibitors against CDKs: Insights for Rational Drug Design
|
journal
|
September 2013 |